Aegis began coverage on shares of DarioHealth Corp. (NASDAQ:DRIO) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $3.50 price target on the stock.

Shares of DarioHealth Corp. (DRIO) opened at 1.96 on Tuesday. The firm’s market capitalization is $19.12 million. DarioHealth Corp. has a 52 week low of $1.81 and a 52 week high of $4.70. The stock’s 50 day moving average price is $2.36 and its 200 day moving average price is $2.85.

DarioHealth Corp. (NASDAQ:DRIO) last released its earnings results on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.13. The firm had revenue of $1.21 million for the quarter. DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. On average, analysts predict that DarioHealth Corp. will post ($0.62) EPS for the current fiscal year.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/02/dariohealth-corp-drio-research-coverage-started-at-aegis.html.

About DarioHealth Corp.

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

Receive News & Stock Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related stocks with our FREE daily email newsletter.